News

Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference
MENDHAM, NJ, October 7, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus ... » Full Release
Antios Therapeutics Announces Presentation at ICE-HBV Toronto Annual Symposium in Conjunction with the International HBV Meeting
MENDHAM, NJ, September 22, 2021 – Antios Therapeutics, Inc. (“Antios”) today announced that Douglas Mayers, M.D., Chief Medical Officer and Co-Founder of Antios, will be giving ... » Full Release
Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. ... » Full Release
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
MENDHAM, N.J. and WARMINSTER, Pa., – Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical ... » Full Release
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients
Antios Therapeutics, Inc. (“Antios”) today announced pharmacokinetic (PK), safety and efficacy data from a Phase 1b clinical trial of ATI-2173, the Company’s Active Site Polymerase Inhibitor Nucleotide (ASPIN), inchronic HBV-infected adult patients. » Full Release
Antios Therapeutics Announces Poster Presentation at the Inaugural HBV-TAG Conference
HBV-TAG: Presentation of in vitro antiviral activity and Phase 1a healthy volunteer data demonstrating the safety, tolerability, and favorable pharmacokinetics of multiple ascending doses of ATI-2173 Pharmacokinetics, ... » Full Release
Antios Therapeutics Continues Building Experienced Executive Team with Appointments of Katie Laessig, M.D., as SVP, Global Regulatory Affairs and Karen Fusaro as SVP, Clinical Operations
Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of a potential curative regimen for ... » Full Release
Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)
SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against HDV MENDHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced that it has dosed the first patients in its Sustained Anti-Viral Efficacy (SAVE) clinical trial, a Phase 2a study of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development as a backbone of a potentially curative regimen for chronic HBV. » Full Release
Antios Therapeutics Raises $96 Million in a Series B Financing
Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and Life Sci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital MENDHAM, N.J., April 12, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc.  » Full Release
Antios Therapeutics Appoints Accomplished Financial Executive, Tamra J. Adams, as its first Chief Financial Officer
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial officer (CFO) effective March 1, 2021. Ms. Adams fills a newly created executive position at Antios as part of the Company’s rapid development. “We have recently completed a Phase 1b clinical trial of our lead asset, ATI-2173, a potential backbone treatment in a functional curative regimen for chronic HBV infection, and anticipate presenting proof-of-concept data from the study in mid-2021,” said Gregory Mayes, chief executive officer of Antios. » Full Release
Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors
Former biopharmaceutical executive has been at the forefront of developing treatments for infectious diseases of the liver including HBV and HCV ATLANTA, GA, Feb. 11, ... » Full Release
Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection
Study results expected to be presented in mid-2021 ATLANTA, GA, Jan. 25, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced that it has ... » Full Release
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as ... » Full Release
Antios Therapeutics Presents at EASL Digital International Liver Congress 2020
ATLANTA, GA, Sept. 3, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a biopharmaceutical company focused on the development of innovative therapies to treat and cure ... » Full Release
Antios Therapeutics Announces Publication Describing Preclinical Profile of ATI-2173
ATLANTA, GA, Sept. 1, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release
Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173
ATLANTA, GA, Feb. 24, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release
Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173
ATLANTA, GA, Feb. 12, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release
Antios Therapeutics to present at HEP DART 2019 Meeting
ATLANTA, GA, Dec. 9, 2019 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a biopharmaceutical company focused on the development of innovative therapies to treat and cure ... » Full Release
Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics announce license for hepatitis B drug
Antios raises $25 million in Series A financing Drug Innovation Ventures at Emory (DRIVE) today announced the licensing of ATI-2173, its leading candidate for the ... » Full Release
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
International Group of Investors from Canada, the U.S. and China Support Former Senior Executives from Pharmasset and Idenix in New Venture ATLANTA, GA, Nov. 27, ... » Full Release